SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-042483
Filing Date
2023-08-14
Accepted
2023-08-14 16:35:36
Documents
51
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q virx-20230630.htm   iXBRL 10-Q 2713879
2 EX-10.2 virx-ex10_2.htm EX-10.2 59859
3 EX-31.1 virx-ex31_1.htm EX-31.1 13520
4 EX-31.2 virx-ex31_2.htm EX-31.2 13526
5 EX-32.1 virx-ex32_1.htm EX-32.1 6251
6 EX-32.2 virx-ex32_2.htm EX-32.2 6187
  Complete submission text file 0000950170-23-042483.txt   9847806

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT virx-20230630.xsd EX-101.SCH 64666
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT virx-20230630_cal.xml EX-101.CAL 40152
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT virx-20230630_lab.xml EX-101.LAB 543172
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT virx-20230630_def.xml EX-101.DEF 279943
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT virx-20230630_pre.xml EX-101.PRE 406736
45 EXTRACTED XBRL INSTANCE DOCUMENT virx-20230630_htm.xml XML 1943275
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51531 | Film No.: 231171191
SIC: 2834 Pharmaceutical Preparations